Skip to main content
. 2019 Nov 25;20(23):5914. doi: 10.3390/ijms20235914

Figure 5.

Figure 5

Emetine enhances the anticancer efficacy of cisplatin and synergizes with cisplatin in the cisplatin-resistant subpopulation of CL1-0 cells. (A) Cells in the cisplatin-resistant subpopulation of CL1-0 cells (CL1-0/CDDP) were exposed to a constant-ratio combination of emetine and cisplatin for 48 hours. Cell viability was measured using an MTS assay. The synergism of emetine and cisplatin was assessed by constructing an isobologram (left) and a Fa-CI plot (right) using the Chou-Talalay equation in CompuSyn software (ComboSyn, Inc.). (B) Cells in the cisplatin-resistant subpopulation of CL1-0 cells (CL1-0/CDDP) were treated with increasing concentrations of cisplatin without or with the combination of 40 nM emetine for 48 hours. Cell viability was measured using an MTS assay. The IC50 values of cisplatin without and with 40 nM emetine were 33.35 μM and 14.27 μM, respectively. The data are shown as the means ± SEMs of 3 independent experiments performed in triplicate.